Epirubicin should not be used in patients with:

Severe heart problems, such as recent heart attack, severe heart failure, or serious arrhythmias.
Previous treatment with the maximum cumulative dose of anthracyclines (due to increased risk of heart damage).
Severe, persistent drug-induced bone marrow suppression (myelosuppression).
Severe liver impairment (high bilirubin levels or Child-Pugh Class C).
Severe hypersensitivity to epirubicin, other anthracyclines, or anthracenediones.

It should also be avoided during the first trimester of pregnancy due to the risk of harm to the fetus. Patients with active infections or those who are immunocompromised should be carefully evaluated before starting treatment.

epirubicin

Common brand names

Approved use in